Modified Vaccinia Ankara: Potential as an Alternative Smallpox Vaccine
Clinical Infectious Diseases2004Vol. 38(12), pp. 1749–1753
Citations Over TimeTop 10% of 2004 papers
Abstract
Despite the declaration of smallpox eradication in 1980, the existence of variola stockpiles and the threat of bioterrorism demand that immunity to smallpox through vaccination be maintained. Although the currently available vaccine was used for the most successful medical intervention ever accomplished, it also is associated with side effects that are difficult to accept in a vaccine for a disease that has not been present for >25 years. Herein, we review alternative approaches to maintaining immunity to smallpox through vaccination with attenuated poxviruses, and we suggest modified vaccinia Ankara (MVA) as a leading candidate for an alternative smallpox vaccine.
Related Papers
- → IMVAMUNE®: modified vaccinia Ankara strain as an attenuated smallpox vaccine(2008)125 cited
- → Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model(2005)89 cited
- → Should Remaining Stockpiles of Smallpox Virus (Variola) Be Destroyed?(2011)21 cited
- → Prevention of Vaccinia Infection in a Laboratory Worker(2007)3 cited
- → Current infection-control issues for smallpox disease and vaccinia vaccine(2003)3 cited